Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Distinct risk groups with different healthcare barriers and acute care use exist in the U.S. population with chronic liver disease

Wong CR, Crespi CM, Glenn B, Han SB, Macinko JA, Bastani R. Distinct risk groups with different healthcare barriers and acute care use exist in[...]

Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?

Gukovskaya AS, Lerch MM, Mayerle J, Sendler M, Ji B, Saluja AK, Gorelick FS, Gukovsky I. Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?[...]

Stricturing Crohn’s Disease: When Biologics May Help or Not?

Fansiwala K, Limketkai BN. Stricturing Crohn's Disease: When Biologics May Help or Not? Inflamm Bowel Dis. 2024 Nov 12:izae264. doi: 10.1093/ibd/izae264. Epub ahead of print.[...]